Search Results

Novartis gains full rights to Cadent’s NMDAr allosteric modulator program, including CAD-9303, a NMDAr-PAM, and MIJ-821, a NMDAr-NAM, which is currently being developed by Novartis under a 2015 license agreement.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, today announced that management will present at the William Blair Biotech Focus Conference on Thursday, August 6, 2020

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, announced that management will participate in the following upcoming virtual investor conferences

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 3, 2020 at 2:00-2:25 pm ET.

Cadent Therapeutics announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the following upcoming investor conferences

Feb. 26, 2020 13:00 UTC Cadent Therapeutics to Present at the Cowen 40 th Annual Health Care Conference CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cadent Therapeutics , a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Cowen 40 th Annual Health Care Conference on Monday, March 2,

Cadent Therapeutics announced that Jodie Morrison has been appointed Chief Executive Officer and has also joined Cadent’s Board of Directors.